Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity

Abstract

Hepatocellular carcinoma (HCC) ranks among the 10 most common cancers worldwide. It evolves from several chronic liver diseases, most of which culminate in cirrhosis. As the most common causes, other than alcoholic cirrhosis, are chronic hepatitis B and C infections, its prevalence worldwide is linked to the prevalence of these two viruses. Thus, the highest rates are in southeast Asia and sub-Saharan Africa, the world's most populous nations, where hepatitis B virus infection is endemic. In most western countries, hepatitis C virus infection is the predominant cause, and hepatitis B-related liver cancer occurs largely among immigrants from countries of high hepatitis B endemicity. In most western countries, the incidence and mortality from HCC is increasing as a consequence of the chronic sequelae of the ‘epidemic’ of hepatitis C of the 1960–1980s. In the US, modeling of this infection predicts a continued rise in liver cancer over the next decade. Surveillance by the National Cancer Institute and the Centers for Disease Control confirms the increasing incidence of and mortality from HCC to the year 2000, although subsequent analyses suggest a slowing or possibly decline in the rate of increase. Whether this trend will continue requires further evaluation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  • Armstrong GL, Alter MJ, McQuillan GM, Margolis HS . (2000). Hepatology 31: 777–782.

  • Beasley RP, Hwang LY, Lin CC, Chien CS . (1981). Lancet 2: 1129–1133.

  • Blumberg BS, Alter HJ, Visnich S . (1965). JAMA 191: 541–546.

  • Bosch FX, Ribes J, Diaz M, Cleries R . (2004). Gastroenterology 127: S5–S16.

  • Bruix J, Barrera JM, Calver X, Ercilla G, Costa J, Sanchez-Tapias JM et al. (1989). Lancet 2: 1004–1006.

  • Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AMS . (2004). Gastroenterology 127: S97–S103.

  • Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M . (1989). Science 244: 359–362.

  • Data available at:http://www.who.int/mediacentre/factsheets/fs164/en/print.html.

  • Data available at:http://srab.cancer.gov/joinpoint/.

  • Davila JA, Morgan RO, Shaib Y, McGlynn A, El-Serag HB . (2004). Gastroenterology 127: 1372–1380.

  • Delarocque-Asatagneau E, Roudot-Thoraval F, Campese C, Desenclos J-C, the Hepatitis C Surveillance System Steering Committee. (2005). Ann Epidemiol 15: 551–557.

  • Deuffic S, Poynard T, Valleron J . (1999). J Viral Hepat 6: 411–413.

  • Dyer Z, Peltakian K, Veldhuyzen van Zanten S . (2005). Aliment Pharmacol Therap 22: 17–22.

  • Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LAF et al. (2005). J Natl Cancer Inst 97: 1407–1427.

  • El-Serag HB . (2002). J Clin Gastroenterol 35 (Suppl 2): S72–S78.

  • El-Serag HB . (2004). Gastroenterology 127: S27–S34.

  • El-Serag HB, Davila J, Petersen N, McGlynn K . (2003). Ann Intern Med 139: 817–823.

  • El-Serag HB, Mason AC . (1999). N Engl J Med 340: 745–750.

  • El-Serag HB, Tran T, Everhart JE . (2004). Gastroenterology 126: 460–468.

  • Ferlay J, Bray F, Pisani P, Parkin DM . (2001). GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide, Version 1.0. Lyon: IARC Press.

    Google Scholar 

  • Hankey BF, Ries LA, Edwards BK . (1999). Cancer Epidemiol Biomarkers Prev 8: 1117–1121.

  • Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL et al. (2002). Hepatology 36: 1206–1213.

  • Hutton MD, Simpson DL, Miller DS, Weir HK, McDavid K, Hall HI . (2001). J Registry Manage 28: 113–120.

  • Kim HJ, Fay MP, Feuer EJ, Midthune DN . (2000). Stat Med 19: 335–351 (correction: 2001;20:655).

  • Lavanchy D . (2004). J Viral Hepatitis 11: 97–107.

  • Marrero JA, Fontana RJ, Su GL, Conveejaram HS, Emick DM, Lok AS . (2002). Hepatology 36: 1349–1354.

  • McGlynn KA, Tsao L, Hsing AW et al. (2001). Int J Cancer 94: 290–296.

  • National Cancer Institute (2005) About SEER. Available athttp://seer.cancer.gov/about/.

  • National Center for Chronic Disease Prevention and Health Promotion (2005) National Program of Cancer Registries-Cancer Surveillance System. June 20, 2005. Available at:http://www.cdc.gov/cancer/npcr/css.htm.

  • Parkin DM, Bray F, Ferlay J, Pisani P . (2001). Int J Cancer 94: 153–156.

  • Parkin DM, Pisani P, Ferlay J . (1999). Int J Cancer 80: 827–841.

  • Reis LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L et al. (eds) (2005). SEER Cancer Statistics Review, 1975–2002. National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2002/.

  • The World health report (2003): shaping the future. World Health Organization, 2003.

  • Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF . (2002). Med Care 40 (suppl 8): IV3–IV18.

  • Wong JB, McQuillan GM, McHutchison JG, Poynard T . (2000). Am J Public Health 20: 1562–1569.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to L B Seeff.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Seeff, L., Hoofnagle, J. Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity. Oncogene 25, 3771–3777 (2006). https://doi.org/10.1038/sj.onc.1209560

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209560

Keywords

This article is cited by

Search

Quick links